REN

Array Technologies, Inc. Reports Financial Results for the Third Quarter 2023 – Continues strong operational execution; announced Chief Financial Officer transition

Retrieved on: 
Tuesday, November 7, 2023
Adjustment, ATI Technologies, REN, Treasury, True North Venture Partners, History, Use, KLA Corporation, EBITDA, Corporation, ASP, GAAP, Acquisition, Brunswick Corporation, ICMS, First Solar, Kelley School of Business, Inflation Reduction Act of 2022, EPS, Employment, DriveTime, Business, Partner, CUST, Micron Technology, Intel, Indiana University, Inflation, Transition system, Uncertainty, STI, Video game, Bank, Pharmaceutical industry, Real estate, Cryptocurrency, Online shopping, Finance, Array

ALBUQUERQUE. N.M., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Array Technologies (NASDAQ: ARRY) (“Array” or “the Company”), a leading provider of tracker solutions and services for utility-scale solar energy projects, today announced financial results for its third quarter ended September 30, 2023.

Key Points: 
  • N.M., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Array Technologies (NASDAQ: ARRY) (“Array” or “the Company”), a leading provider of tracker solutions and services for utility-scale solar energy projects, today announced financial results for its third quarter ended September 30, 2023.
  • “Despite the near-term secular challenges which impacted our volume when compared to the prior year, Array again delivered another strong quarter across all of our key metrics.
  • We are seeing a steady increase in our domestic pipeline, which has more than doubled from the second quarter.
  • Today the Company also announced that Kurt Wood has been named Chief Financial Officer effective November 13, 2023.

Portugal Data Center Market Report 2023: Investment Analysis & Growth Opportunities to 2028 Featuring Key Investors - Altice Portugal, Ar Telecom, Equinix, NOS Sistemas, WebTuga, and REN - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Technology, Data Management, Investment, Peninsula, Altice Portugal, Government, Commerce, USD, CAP, Quark, RESEARCH, Equinix, Growth, Sistema de Informações da República Portuguesa, Altice, REN, Retail, Renewable energy

The "Portugal Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Portugal Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The introduction of 5G technology in Portugal has provided a strong foundation for further growth in the data center market.
  • Key investors in the Portugal data center market include Altice Portugal, Ar Telecom, Equinix, NOS Sistemas, WebTuga, and REN, among others.
  • A detailed study of the existing Portugal data center market landscape, an in-depth industry analysis, and insightful predictions about market size during the forecast period.

First Migraine Neuroband Addressing Unmet Needs of Adolescents to Debut at 2023 Child Neurology Society Annual Meeting

Retrieved on: 
Thursday, September 28, 2023
REN, University Hospital, New Orleans, Quality of life, CNS, Cincinnati Children's Hospital Medical Center, Risk, CPM, Hospital, Texas Tech University Health Sciences Center El Paso, Birth control, Pharmaceutical industry, Cheese, Migraine, MD

NETANYA, Israel and BRIDGEWATER, N.J., Sept. 28, 2023 /PRNewswire/ -- Theranica, a neuromodulation therapeutics company, is exhibiting and presenting at the upcoming 52nd Annual Child Neurology Society Meeting (CNS)(Booth #209), where they will present Nerivio®, the first and only dual-use (acute and preventive) migraine neuroband purpose-built for adolescents with migraine disease.

Key Points: 
  • "Reducing disability and frequency of migraine attacks in children and adolescents improves their quality of life and potentially decreases risk of conversion to chronic migraine.
  • The recent expanded indication of the Nerivio migraine neuroband represents a distinctive dual-use treatment to reduce the occurrence of migraine episodes and relief their symptoms upon onset."
  • Migraine disease affects 1 billion people worldwide, 10 percent of which are children, with far-reaching consequences that can't be ignored.
  • According to Alon Ironi, the CEO and co-founder of Theranica, "Our goal at Theranica has always been focused on addressing significant unmet clinical needs.

NERIVIO® CE MARK INDICATION EXPANDED TO PREVENTIVE AND ACUTE TREATMENT OF MIGRAINE FOR ADOLESCENTS AND ADULTS

Retrieved on: 
Wednesday, August 9, 2023
CE, Migraine, REN, University, Therapy, Prevalence, Life, Disability, Brain, MDR, Patient, Disease, CPM, Neurology, Research, University of L'Aquila, Pharmaceutical industry

NETANYA, Israel, Aug. 9, 2023 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, today announced it received expanded CE (Conformité Européenne) mark approval under MDR European regulation for Nerivio® as dual-use therapy for both acute and preventive treatment of migraine for adults and adolescents. The CE mark expansion for Nerivio is a critical milestone to accelerate the availability of the novel, drug-free migraine device into the European market.

Key Points: 
  • The CE mark expansion for Nerivio is a critical milestone to accelerate the availability of the novel, drug-free migraine device into the European market.
  • Nerivio has been available with prescription in the USA since 2020, initially for acute treatment and since April this year also as a preventive treatment.
  • "It is important to expand the treatment options with a non-pharmacological treatment, especially one that can both treat and prevent migraine."
  • Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment.

NERIVIO® CE MARK INDICATION EXPANDED TO PREVENTIVE AND ACUTE TREATMENT OF MIGRAINE FOR ADOLESCENTS AND ADULTS

Retrieved on: 
Wednesday, August 9, 2023
CE, Migraine, REN, University, Therapy, Prevalence, Life, Disability, Brain, MDR, Patient, Disease, CPM, Neurology, Research, University of L'Aquila, Pharmaceutical industry

NETANYA, Israel, Aug. 9, 2023 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, today announced it received expanded CE (Conformité Européenne) mark approval under MDR European regulation for Nerivio® as dual-use therapy for both acute and preventive treatment of migraine for adults and adolescents. The CE mark expansion for Nerivio is a critical milestone to accelerate the availability of the novel, drug-free migraine device into the European market.

Key Points: 
  • The CE mark expansion for Nerivio is a critical milestone to accelerate the availability of the novel, drug-free migraine device into the European market.
  • Nerivio has been available with prescription in the USA since 2020, initially for acute treatment and since April this year also as a preventive treatment.
  • "It is important to expand the treatment options with a non-pharmacological treatment, especially one that can both treat and prevent migraine."
  • Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment.

Clinical Study Evaluated Safety of Using Nerivio® for Treating Migraine in Pregnant Women

Retrieved on: 
Wednesday, June 21, 2023
Migraine, Pregnancy, REN, Pre-eclampsia, Gestational age, Fetus, Headache (journal), Fear, Quality of life, Hope, Woman, Brain, Risk, History, Doctor of Philosophy, Pain, MD, Patient, Paracetamol, Stanford University School of Medicine, CPM, Neurology, Lactation, Health, FDA, Family, Safety, Birth control, Medical imaging, Headache

NETANYA, Israel and BRIDGEWATER, N.J., June 21, 2023 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company, announced the results of a study recently published in Headache demonstrating the safety of the Nerivio® migraine bioband, a novel Remote Electrical Neuromodulation (REN) wearable, as a drug-free treatment for pregnant women with migraine.

Key Points: 
  • The study demonstrates the Nerivio migraine bioband's safety as a migraine treatment for pregnant women while reinforcing its efficacy as seen in previous studies.
  • Additionally, pregnant women with a history of migraine are at higher risk than those without migraine for adverse pregnancy outcomes, such as low birth weight, preterm birth, and pre-eclampsia.
  • The controlled study ( NCT05464069 ) consisted of a retrospective survey of women with migraine between 18 - 45 years of age who were pregnant during the study period.
  • "While more targeted studies in pregnant women with migraine are needed, this study offers hope for those seeking effective and safe interventions for migraine during pregnancy."

Using Nerivio® for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits for Patients, Insurers, and Employers, According to a New Health Economics Study

Retrieved on: 
Tuesday, May 16, 2023
Presenteeism, Migraine, Insurance, REN, Therapy, Life, International Classification of Functioning, Disability and Health, Stanford University, Patient satisfaction, Headache (journal), Absenteeism, AHS, Quality of life, Research, Brain, Headache, Journal of Medical Economics, Health, Journal, Stanford University Medical Center, Work, MD, Patient, Pain management, CPM, Neurological disorder, FDA, Health insurance, Pharmaceutical industry, Medical imaging

NETANYA, Israel and BRIDGEWATER, N.J., May 16, 2023 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, announced the results of a recent study published in the Journal of Medical Economics, showing that Nerivio®, a novel Remote Electrical Neuromodulation (REN) wearable, provides significant cost savings in addition to clinical benefits when used as a preventive migraine treatment.

Key Points: 
  • The randomized, double-blind, placebo-controlled trial aimed to assess the clinical benefits and associated cost savings from use of REN with Nerivio for migraine prevention.
  • Participants treated with either Nerivio or a placebo device every other day for prevention of migraine.
  • Health insurance systems and employers should consider the powerful financial incentives that come with this drug-free migraine treatment."
  • Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment.

GOLD ROYALTY REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Retrieved on: 
Thursday, May 11, 2023
Odyssey, REN, Osisko Gold Royalties, Barrick, Bank statement, Sustainability reporting, NSR, Iamgold, Granite Creek, François Fénelon, Gold, NPI, National instrument, Ogee, Agnico Eagle, Barrick Gold, Security (finance), Mining, Cryptocurrency, Rare-earth element

Odyssey Project (3.0% NSR over the northern portion of the project): On April 27, 2023, Agnico Eagle Mines Limited announced its 2023 first quarter results including an update on the Odyssey Project.

Key Points: 
  • Odyssey Project (3.0% NSR over the northern portion of the project): On April 27, 2023, Agnico Eagle Mines Limited announced its 2023 first quarter results including an update on the Odyssey Project.
  • Good progress was made on underground development and surface construction activities at the Odyssey Project in the first quarter of 2023.
  • Fenelon Gold Project (2.0% NSR royalty over the majority of the project): On January 17, 2023, Wallbridge Mining Company Limited announced an updated NI 43-101 mineral resource estimate for the Fenelon Gold project.
  • Granite Creek Mine Project (10.0% NPI): On April 3, 2023, i-80 Gold Corp. provided a comprehensive update on its 2023 exploration and development programs.

Theranica's Nerivio® Cleared by FDA for Preventive Treatment of Migraine

Retrieved on: 
Tuesday, February 28, 2023
DSM-IV codes, Headache (journal), Headache, University of Washington School of Medicine, Safety, News, Migraine, MD, Pain, Physician, Research, FDA, Food and Drug Administration, Patient, Sympathetic nervous system, CPM, Education, Geisel School of Medicine, Therapy, Nausea, Adolescence, Plasma protein binding, Smartphone, REN, Dartmouth, Head, Neurology, Food, Contract management, Prevalence, Pharmaceutical industry, Birth control, Relaxation

NETANYA, Israel and BRIDGEWATER, N.J., Feb. 28, 2023 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, today announced that the Nerivio® prescription wearable recently received Food and Drug Administration (FDA) clearance as a dual-use acute and preventive treatment for migraine with or without aura in people 12 years of age or older. In a randomized placebo-controlled study, the drug-free Nerivio, used every other day, demonstrated significant reduction in monthly migraine days and other prevention endpoints.

Key Points: 
  • Nerivio is a novel, physician-prescribed treatment for migraine that is discreet and non-disruptive to everyday living.
  • Each treatment lasts 45 minutes and is recommended for use every other day for prevention or at the start of a migraine attack for acute treatment.
  • For Alon Ironi, Theranica CEO and co-founder, the expanded FDA indication for preventive treatment in adolescent patients has personal meaning.
  • With FDA clearance of the device, its availability and potential use for preventive and acute treatment is welcome news for both physicians and patients."

Arkose Labs Appoints Frank Teruel as new Chief Financial Officer

Retrieved on: 
Tuesday, February 7, 2023
CFO, Digital, Santa Clara University, USS Incessant (AM-248), SVP, SCU Leavey School of Business, REL, RELX, Business, News, Sale, Research, Intelligence, REN, SAN, Computer security, Management, Cryptocurrency

SAN MATEO, Calif., Feb. 7, 2023 /PRNewswire/ -- Arkose Labs, the global leader in bot management and account security, today announced that Frank Teruel has joined the company as its new CFO. Teruel will serve on the Executive Leadership Team and report directly to founder and CEO Kevin Gosschalk.

Key Points: 
  • SAN MATEO, Calif., Feb. 7, 2023 /PRNewswire/ -- Arkose Labs , the global leader in bot management and account security, today announced that Frank Teruel has joined the company as its new CFO.
  • Cybersecurity and identity expert Frank Teruel selected to lead Arkose Labs' corporate services and finance org.
  • Teruel said, "I'm delighted to join the Arkose Labs leadership team at this critical juncture of continued high growth and scale.
  • Add its industry leading 1-million-dollar credential stuffing warranty, and Arkose Labs is positioned as the clear leader and innovator in our space."